This single-arm, open-label, non-randomized study will evaluate the effect of danoprevir/ritonavir on the pharmacokinetics of escitalopram and S-demethylcitalopram in healthy volunteers. Healthy volunteers will receive oral doses of danoprevir/ritonavir and escitalopram. The anticipated time of the study is 6 weeks.

Inclusion Criteria:

• Adult healthy volunteers, aged 18 to 55 years, inclusive
• Body mass index (BMI) 18.0 to 32.0 kg, inclusive
• Absence of evidence of any active or chronic disease
• Non-smokers

Exclusion Criteria:

• Presence of any active or chronic disease
• Abnormal blood pressure
• Abnormal resting heart rate
• Abnormal ECG values
• History of any clinically significant cardiovascular or cerebrovascular disease